Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765479785> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2765479785 endingPage "A570" @default.
- W2765479785 startingPage "A569" @default.
- W2765479785 abstract "NICE defines ultra-orphan drugs as those treating life-threatening or seriously debilitating conditions affecting ≤1:50,000 people and developed the HST programme to assess these drugs, which are unlikely to meet standard HTA criteria. We compare outcomes of HST evaluations with assessment by HAS and the G-BA. HST final evaluations published by June 2017 were identified (n=7). HAS and G-BA evaluations of the same drugs were then identified. The HST programme assessed unmet need, cost to NHS/personal social services, and value for money. NICE recommended six of the seven drugs, three outright, two with managed access agreements (MAAs) requiring additional data collection to account for uncertainty, and one for a subpopulation with an MAA. Despite acknowledgement of clinical need and likely benefit, sebelipase-α was not recommended because of high costs. HAS consider additional benefit (ASMR) of orphan drugs with expected budget impact (BI) <€30 million/year to be proven at marketing authorisation. However, the drugs reviewed here were assessed through normal processes. HAS considered six drugs to provide additional benefit (two ASMR II, one ASMR III, three ASMR IV) but requested additional data for each, due to uncertainty. Eliglustat received ASMR V. Sebilipase-α (ASMR IV) was withdrawn by the manufacturer, suggesting that price agreement was not reached. The G-BA assume additional benefit for orphan drugs based on marketing authorisation. The remaining criterion was assessment of expected BI, with a threshold of €50 million/year in the first three years. All seven drugs were recommended, three with validation periods. While HTAs of ultra-orphan technologies were largely based on clinical benefit and BI, and all three bodies requested follow-up data to manage uncertainty, their recommendations varied. As further high-cost ultra-orphan drugs are introduced, additional criteria, such as the HST QALY threshold, may be considered to manage combined BI." @default.
- W2765479785 created "2017-11-10" @default.
- W2765479785 creator A5000827855 @default.
- W2765479785 creator A5002480333 @default.
- W2765479785 creator A5011596964 @default.
- W2765479785 creator A5036667571 @default.
- W2765479785 date "2017-10-01" @default.
- W2765479785 modified "2023-09-29" @default.
- W2765479785 title "A Comparison of The Nice Highly Specialised Technology (HST) Programme with Assessment By The National Authority For Health (HAS; France), And The Federal Joint Committee (G-BA; Germany)" @default.
- W2765479785 doi "https://doi.org/10.1016/j.jval.2017.08.970" @default.
- W2765479785 hasPublicationYear "2017" @default.
- W2765479785 type Work @default.
- W2765479785 sameAs 2765479785 @default.
- W2765479785 citedByCount "1" @default.
- W2765479785 countsByYear W27654797852022 @default.
- W2765479785 crossrefType "journal-article" @default.
- W2765479785 hasAuthorship W2765479785A5000827855 @default.
- W2765479785 hasAuthorship W2765479785A5002480333 @default.
- W2765479785 hasAuthorship W2765479785A5011596964 @default.
- W2765479785 hasAuthorship W2765479785A5036667571 @default.
- W2765479785 hasBestOaLocation W27654797851 @default.
- W2765479785 hasConcept C100001284 @default.
- W2765479785 hasConcept C108759981 @default.
- W2765479785 hasConcept C127413603 @default.
- W2765479785 hasConcept C142724271 @default.
- W2765479785 hasConcept C144133560 @default.
- W2765479785 hasConcept C162118730 @default.
- W2765479785 hasConcept C162324750 @default.
- W2765479785 hasConcept C199360897 @default.
- W2765479785 hasConcept C2776125615 @default.
- W2765479785 hasConcept C2777589142 @default.
- W2765479785 hasConcept C2777880217 @default.
- W2765479785 hasConcept C2779256446 @default.
- W2765479785 hasConcept C38652104 @default.
- W2765479785 hasConcept C41008148 @default.
- W2765479785 hasConcept C42475967 @default.
- W2765479785 hasConcept C512399662 @default.
- W2765479785 hasConcept C60644358 @default.
- W2765479785 hasConcept C71924100 @default.
- W2765479785 hasConcept C75480439 @default.
- W2765479785 hasConcept C86803240 @default.
- W2765479785 hasConceptScore W2765479785C100001284 @default.
- W2765479785 hasConceptScore W2765479785C108759981 @default.
- W2765479785 hasConceptScore W2765479785C127413603 @default.
- W2765479785 hasConceptScore W2765479785C142724271 @default.
- W2765479785 hasConceptScore W2765479785C144133560 @default.
- W2765479785 hasConceptScore W2765479785C162118730 @default.
- W2765479785 hasConceptScore W2765479785C162324750 @default.
- W2765479785 hasConceptScore W2765479785C199360897 @default.
- W2765479785 hasConceptScore W2765479785C2776125615 @default.
- W2765479785 hasConceptScore W2765479785C2777589142 @default.
- W2765479785 hasConceptScore W2765479785C2777880217 @default.
- W2765479785 hasConceptScore W2765479785C2779256446 @default.
- W2765479785 hasConceptScore W2765479785C38652104 @default.
- W2765479785 hasConceptScore W2765479785C41008148 @default.
- W2765479785 hasConceptScore W2765479785C42475967 @default.
- W2765479785 hasConceptScore W2765479785C512399662 @default.
- W2765479785 hasConceptScore W2765479785C60644358 @default.
- W2765479785 hasConceptScore W2765479785C71924100 @default.
- W2765479785 hasConceptScore W2765479785C75480439 @default.
- W2765479785 hasConceptScore W2765479785C86803240 @default.
- W2765479785 hasIssue "9" @default.
- W2765479785 hasLocation W27654797851 @default.
- W2765479785 hasOpenAccess W2765479785 @default.
- W2765479785 hasPrimaryLocation W27654797851 @default.
- W2765479785 hasRelatedWork W1978219245 @default.
- W2765479785 hasRelatedWork W1991412514 @default.
- W2765479785 hasRelatedWork W2051366497 @default.
- W2765479785 hasRelatedWork W22610855 @default.
- W2765479785 hasRelatedWork W2765479785 @default.
- W2765479785 hasRelatedWork W2997997888 @default.
- W2765479785 hasRelatedWork W3110896141 @default.
- W2765479785 hasRelatedWork W3112012488 @default.
- W2765479785 hasRelatedWork W3124149350 @default.
- W2765479785 hasRelatedWork W4243569480 @default.
- W2765479785 hasVolume "20" @default.
- W2765479785 isParatext "false" @default.
- W2765479785 isRetracted "false" @default.
- W2765479785 magId "2765479785" @default.
- W2765479785 workType "article" @default.